The Rome Statement for an HIV Cure
Major HIV/AIDS Stakeholders Call for HIV Cure Research to be Accelerated
The year 2011 marked 30 years since the first AIDS cases were reported. During these three decades significant progress has been made in the global response against the HIV/AIDS epidemic. In particular, development of efficient antiretroviral drugs and their expanding availability have ensured that millions of people living with HIV live a healthy life.
Nevertheless, while the benefit of antiretroviral treatment is irrefutable, the maintenance of a persistent infection in patients despite years of antiretroviral therapy precludes any discontinuation of treatment. This life-long requirement is both an individual and public health burden. In addition, for every person starting antiretroviral treatment, two new infections occur . In a context of global economic crisis with the resulting pressure on international funding of the HIV/AIDS response, the long-term sustainability of treatment rollout is in jeopardy. The recent change in the WHO guidelines recommending an earlier initiation of HIV treatment makes the situation even more challenging. Investments to develop new therapeutic strategies that will ultimately allow HIV infected patients to discontinue their treatment are of the utmost urgency.
Recent scientific advances in HIV research have led to a re-emergence of interest and optimism in the prospects of a cure for HIV. The development of, at least, a functional cure that, without completely eliminating the virus from the body, would permanently suppress its replication and considerably diminish viral reservoirs, possibly leading to the long-term remission of patients. Not only would such a strategy act as therapy at the individual level but, considering the growing evidence that HIV transmission is dramatically reduced in the absence of detectable viral load, it would most probably contribute to HIV prevention at the population level. Nevertheless, these efforts should come in addition to the current treatment rollout and prevention strategies.
A functional HIV cure can only be achieved through an increased and concerted international effort engaging not only the scientific community but all stakeholders involved in the HIV/AIDS response and global health.
Under the auspices of the International AIDS Society, a group of internationally recognized scientists and stakeholders developed a Global Scientific Strategy:Towards an HIV Cure. The strategy aims at building a global consensus on the state of the HIV reservoirs research and defining scientific priorities that need to be addressed by future research to tackle HIV persistence in patients undergoing antiretroviral therapy.
As members of the Advisory Board of the Towards an HIV Cure:
Now, more than ever, it is time to seriously start looking for an HIV cure.
- We recognize the importance of developing a safe, accessible and scalable HIV cure as a therapeutic and preventive strategy against HIV infection and to help control the AIDS epidemic.
- We are committed to stimulating international and multidisciplinary research collaborations in the field of HIV cure research.
- We encourage other stakeholders, international leaders and organizations to contribute to accelerating HIV cure research through their own initiatives and/or by endorsing this statement and supporting the alliance we are building.
Sign the Rome Statement here
Advisory Board Members – Global Scientific Strategy “Towards an HIV Cure”:
Bertrand Audoin, International AIDS Society
Craig McClure, World Health Organization
Françoise Barré-Sinoussi, International AIDS Society
Jack Whitescarver, United States National Institutes of Health
Jean-François Delfraissy, French Agence Nationale de Recherche sur le Sida et les Hépatites Virales
Mark Harrington, Treatment Action Group
Nikos Dedes, International Treatment Preparedness Coalition
Paola de Carli,Sidaction
Paula Munderi, MRC/UVRI Uganda Research Unit on AIDS
Rowena Johnston, amfAR, The Foundation for AIDS Research
International Working Group Members – Global Scientific Strategy “Towards an HIV Cure”:
Alain Lafeuillade, Toulon General Hospital, France
Alan Landay, Rush University Medical Center, USA
Amalio Telenti, University of Lausanne, Switzerland
Ann Woolfrey, Fred Hutchinson Cancer Research Center, USA
Ben Berkhout, University of Amsterdam, The Netherlands
Carine Van Lint, University of Brussels, Belgium
Christine Katlama, Pitié-Salpêtrière Hospital, France
David Margolis, University of North Carolina at Chapel Hill, USA
Eric Verdin, University of California, San Francisco, USA
Frank Maldarelli, NCI/NIH, USA Guido Poli, San Raffaele University and Scientific Institute, Italy
Guido Silvestri, Emory University School of Medicine, USA
Javier Martinez-Picado, Foundation Germans Trias I Pujol for Biomedical Research, Spain
Jean-Pierre Routy, McGill University, Canada
Jim Mullins, University of Washington, USA
John Mellors, University of Pittsburgh, USA
John Zaia, Beckman Research Institute of City of Hope, USA
Mario Stevenson, University of Miami Medical School, USA
Martin Markowitz, Aaron Diamond AIDS Research Center, USA
Melissa Churchill, Burnet Institute, Australia
Michael Lederman, Case Western Reserve University, USA
Michele Di Mascio, NIAID/NIH, USA
Nicolas Chomont, VGTI- Florida, USA
Sarah Palmer, Karolinska Institute, Sweden
Sharon Lewin, The Alfred, Monash University and Burnet Institute, Australia
Steven Deeks, University of California, San Francisco, USA
David Haerry. European Aids Treatment Group
Stefano Vella, Istituto Superiore di Sanita, IAS 2011 Co-Chair
Download the PDF version of this statement
Download the press release